Related Experiment Video
Updated: Jul 17, 2025
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
hPSC-derived RPE transplantation for the treatment of macular degeneration
Qian Liu1, Jun Liu1, Akon Higuchi2
1State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
Abstract:
Macular degeneration (MD) is a group of diseases characterized by irreversible and progressive vision loss. Patients with MD suffer from severely impaired central vision, especially elderly people. Currently, only one type of MD, wet age-related macular degeneration (AMD), can be treated with anti-vascular endothelium growth factor (VEGF) drugs. Other types of MD remain difficult to treat. With the advent of human pluripotent stem cells (hPSCs) and their differentiation into retinal pigmented epithelium (RPE), it is promising to treat patients with MD by transplantation of hPSC-derived RPE into the subretinal space. In this review, the current progress in hPSC-derived RPE transplantation for the treatment of patients with MD is described from bench to bedside, including hPSC differentiation into RPE and the characterization and usage of hPSC-derived RPE for transplantation into patients with MD.
Insights
Human pluripotent stem cells offer a promising treatment for macular degeneration (MD) by generating retinal pigmented epithelium (RPE) for transplantation. This approach aims to restore vision for patients with MD, particularly the elderly.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Stem Cell Biology
Background:
- Macular degeneration (MD) causes irreversible central vision loss, primarily affecting the elderly.
- Current treatments are limited, with only wet age-related macular degeneration (AMD) responsive to anti-VEGF therapies.
- Other forms of MD present significant unmet clinical needs.
Approach:
- Utilizing human pluripotent stem cells (hPSCs) to differentiate into retinal pigmented epithelium (RPE).
- Developing transplantation protocols for hPSC-derived RPE into the subretinal space.
- Characterizing the safety and efficacy of hPSC-derived RPE for clinical application.
Key Points:
- hPSC differentiation protocols yield functional RPE cells.
- Transplantation of hPSC-derived RPE shows potential for vision restoration in MD models.
- The review covers the bench-to-bedside progression of this therapeutic strategy.
Conclusions:
- hPSC-derived RPE transplantation is a promising therapeutic avenue for treating various forms of MD.
- This regenerative medicine approach offers hope for patients with limited treatment options.
- Further clinical translation is anticipated to address vision loss in MD.
